Results 231 to 240 of about 106,669 (305)

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang   +4 more
wiley   +1 more source

GMP‐compliant production, validation and dosimetry of clinical grade [18F]3‐(3‐fluoropropyl)‐2‐phenyl‐2,3‐dihydrobenzo[d]thiazole ([18F]FPBT) for oxidative stress PET imaging

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Oxidative stress plays a critical role in the pathophysiology of various diseases, yet current methods for its non‐invasive detection remain limited. This study aimed to systematically validate a superoxide‐selective PET tracer, [18F]FPBT, for the early diagnosis and therapeutic monitoring of oxidative stress‐related conditions ...
Hua Zhang   +10 more
wiley   +1 more source

Tumor‐Derived Exosomal piR‐hsa‐28212 Promotes Lymphatic Metastasis in Breast Cancer

open access: yesCancer Science, EarlyView.
Breast cancer–derived exosomal piR‐hsa‐28212 promotes lymphangiogenesis and lymph node metastasis by activating VEGFC/VEGFR3 signaling. It stabilizes TBX1 mRNA in lymphatic endothelial cells and METTL3 protein in tumor cells, enhancing VEGFR3 expression and VEGFC secretion.
Yafen Wang   +7 more
wiley   +1 more source

NTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2

open access: yesCancer Science, EarlyView.
Copy number variation analysis in The Cancer Genome Atlas identified NTAQ1 as a potential driver of HCC progression. NTAQ1 accelerates tumor growth by promoting the degradation of the tumor suppressor protein PRDM2, thereby impairing DNA repair and suppressing apoptosis. These findings indicate that NTAQ1 could be a valuable target for the treatment of
Tomohiko Ikehara   +21 more
wiley   +1 more source

Primary bladder neck obstruction in men-new perspectives in physiopathology. [PDF]

open access: yesProstate Cancer Prostatic Dis
Cash H   +4 more
europepmc   +1 more source

Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort

open access: yesCancer Science, EarlyView.
Off‐label nivolumab treatment guided by CGP results was evaluated in 56 patients with advanced solid tumors. TMB‐High was the predominant biomarker leading to nivolumab treatment. Nivolumab showed limited clinical benefit in 50 patients with measurable disease, with an ORR of 16.0%, DCR of 40.0%, median PFS of 2.7 months, and median OS of 7.2 months ...
Masashi Kanai   +16 more
wiley   +1 more source

Unsampled large cribriform and intraductal carcinoma and the limits of risk stratification by prostate biopsy

open access: yes
BJU International, EarlyView.
Mohamad Watfa   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy